4 Healthcare Stock Stories To Close the Trading Week

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Biogen IDEC (NASDAQ: BIIB): Closing price $178.00

Biogen has received a positive opinion from the Committee for Medicinal Products for Human Use in the European Union, recommending a marketing authorization be granted for Tecfidera (dimethyl fumarate) as a first-line oral treatment for adults suffering from relapsing-remitting multiple sclerosis. The Committee, on the basis of quality, safety and efficacy data submitted by Biogen Idec, considers there to be a favorable benefit-to-risk balance for the drug. The recommendation is now referred to the European Commission, which grants marketing authorization for medicines in the European Union. The FDA should make a decision on the marketing application for Tecfidera in the United States in the coming days.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BIIB

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business